Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

Earlier this month, Costco Wholesale Corporation reported strong fiscal Q4 2025 earnings and announced a new partnership with ...

Lilly's GIP/GLP-1 agonist Mounjaro (tirzepatide) also outperformed Ozempic, and the formulation of the drug for obesity, ...

The analysts see “meaningful skew to the downside” as around one-third of Roche’s 2030 revenue is at risk from competitors ...

Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

The company will scale its weight loss offerings ahead of generic GLP-1s coming to the Canadian market in 2026.

In 2025, U.S. families with employer-sponsored health insurance face an increase in premiums, now averaging nearly $27,000 ...

At this month’s Food and Nutrition Conference and Expo in Nashville, one buzzword dominated conversations – GLP-1 medications ...